Novel presenilin 1 and 2 double knock-out cell line for in vitro validation of PSEN1 and PSEN2 mutations

Keyphrases

• In Vitro Validation 100%
• Double Knockout 100%
• Presenilin 2 100%
• Presenilin 2 mutation 100%
• Presenilin-1 (PSEN1) 100%
• Secretase 57%
• Pathogenicity 42%
• Clinical Trials 28%
• Novel Variant 28%
• Neuropathology 14%
• Clinical Presentation 14%
• Alzheimer's Disease 14%
• Early Onset 14%
• Patient Assessment 14%
• Amyloid Precursor Protein 14%
• Scientific Community 14%
• Autosomal Dominant 14%
• Presenilin 1 mutation 14%
• Biochemical Studies 14%
• Pathological Features 14%
• Family History 14%
• Novel mutation 14%
• Amyloid Plaques 14%
• Cas9 Protein 14%
• Variants of Uncertain Significance 14%
• Biochemical Tests 14%
• Glycosylation 14%
• Clinical Observation 14%
• Nicastrin 14%
• Complete Ablation 14%
• Novel Cell Line 14%
• Varying Effects 14%
• Barriers to Recruitment 14%
• Alzheime's Disease 14%
• DNA Sequence Data 14%
• Amyloid Precursor Protein Processing 14%
• Familial Form 14%
• Variant Effect 14%
• Mouse Neuroblastoma Cell 14%

Neuroscience

• In Vitro 100%
• Presenilin 1 100%
• Cell Line 100%
• Presenilin 2 100%
• Secretase 57%
• Amyloid Precursor Protein 28%
• Amyloid Protein 28%
• Alzheimer's Disease 14%
• Posttranslational Modification 14%
• DNA Sequencing 14%
• Presenilin 14%
• Neuroblastoma 14%
• CRISPR 14%
• Nicastrin 14%
• Glycosylation 14%
• Plaque 14%
• Biological Marker 14%
• Peptide 14%

Biochemistry, Genetics and Molecular Biology

• Presenilin 100%
• Secretase 33%
• Clinical Trial 16%
• Amyloid Precursor Protein 16%
• Amyloid Protein 16%
• DNA Sequence 8%
• Secretion (Process) 8%
• Posttranslational Modification 8%
• Glycosylation 8%
• Autosomal Dominant Inheritance 8%
• CRISPR/Cas9 8%
• Nicastrin 8%
• Biochemical Testing 8%
• Peptide 8%